Require commercial health plans and Medicaid to cover biomarker testing for early detection, risk stratification, diagnosis, treatment, and management of Alzheimer’s disease for adults over 50.

Jake Auchincloss · Massachusetts · Democratic

policy impact 0.73 specificity 0.94 extraction confidence 90%

Commitment kind: unknown. Promised action: not established. Promised outcome: not established. Deadline: unknown; not assumed expired.

Occurrences

This legislation would require commercial health plans and Medicaid to cover biomarker testing for early detection, risk stratification, diagnosis, treatment, and management of Alzheimer’s disease for adults over 50.

Auchincloss introduced the Alzheimer’s Early Detection Act, which would require commercial health plans and Medicaid to cover Alzheimer’s biomarker testing for adults over 50.

Reps. Auchincloss, Ciscomani Introduce the Bipartisan Alzheimer’s Early Detection Act to Expand Coverage for Pre-Symptomatic Disease Detection | U.S. Congressman Jake Auchincloss Of Massachusetts 4th District
primary · press_release · model gpt-5.5

Evidence

verified · Source version 91432 · locator 2645

This legislation would require commercial health plans and Medicaid to cover biomarker testing for early detection, risk stratification, diagnosis, treatment, and management of Alzheimer’s disease for adults over 50.

Fetched verbatim passage. AI summary (separate from source): Auchincloss announced a bill matching the commitment, but the language describes what the legislation would do rather than an enacted requirement.

unresolved same_term A for effort

Reps. Auchincloss, Ciscomani Introduce the Bipartisan Alzheimer’s Early Detection Act to Expand Coverage for Pre-Symptomatic Disease Detection | U.S. Congressman Jake Auchincloss Of Massachusetts 4th District
primary · model gpt-5.5 · confidence 94%

verified · Source version 91434 · locator 1267

Mr. Auchincloss (for himself and Mr. Ciscomani) introduced the following bill; which was referred to the Committee on Energy and Commerce

Fetched verbatim passage. AI summary (separate from source): GovInfo records the measure as introduced and referred to committee, showing legislative effort but no enacted coverage mandate.

unresolved same_term A for effort

H.R. 9823 (IH) - Alzheimer’s Early Detection Act of 2026 - BILLS-119hr9823ih | Content Details | GovInfo
secondary · model gpt-5.5 · confidence 96%

unverified · Source version 91434 · locator unknown

Last Action Date Listed July 22, 2026

Unverified model/legacy excerpt; not proof. AI summary (separate from source): The official GovInfo record lists the last action as July 22, 2026, with no later enacted or passage action shown during the September 15-October 14, 2026 lookback window.

unresolved same_term A for effort

H.R. 9823 (IH) - Alzheimer’s Early Detection Act of 2026 - BILLS-119hr9823ih | Content Details | GovInfo
secondary · model gpt-5.5 · confidence 93%

unverified · Source version 91436 · locator unknown

A group health plan and a health insurance issuer offering group or individual health insurance coverage shall provide benefits under such plan or coverage for Alzherimer’s biomarker testing.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): The introduced bill text would require private-plan coverage for Alzheimer’s biomarker testing, but it remains proposed statutory language rather than enacted law.

unresolved same_term A for effort

BILLS-119hr9823ih.pdf
secondary · model gpt-5.5 · confidence 94%

unverified · Source version 91436 · locator unknown

The amendments made by this subsection shall apply with respect to calendar quarters beginning on or after the date that is 1 year after the date of the enactment of this Act.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): The Medicaid coverage provision is explicitly contingent on enactment, supporting an unresolved status absent evidence that H.R. 9823 became law.

unresolved same_term A for effort

BILLS-119hr9823ih.pdf
secondary · model gpt-5.5 · confidence 92%

unverified · Source version 91438 · locator unknown

Introduced July 22, 2026 Lastest Action July 22, 2026 - Referred to the House Committee on Energy and Commerce.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): The House floor record likewise shows H.R. 9823 at referral, with no House passage or enactment shown for this commitment.

unresolved same_term A for effort

live.house.gov, U.S. House of Representatives
secondary · model gpt-5.5 · confidence 91%

Assessments

Public state: pending As of 2026-10-14 · verified · . Original AI recommendation (not independently established): unresolved. unknown A for effort

The verified commitment concerns an outcome: requiring commercial health plans and Medicaid to cover Alzheimer’s biomarker testing for adults over 50. Verified evidence shows Auchincloss introduced legislation that would create that requirement, and that the bill was referred to committee, which is material effort by the candidate. However, the verified evidence does not show enactment or implementation of the coverage mandate, and there is no documented deadline that has expired as of 2026-10-14. Introduction of a bill does not fulfill an outcome promise to require coverage.

provider codex_cli · model gpt-5.5 · confidence 94%